

A variance-component score test for the comparison of gene-set transcriptomic profiles of vaccines

Arthur Hughes¹², Denis Agniel⁴⁵,
Rodolphe Thiébaut¹²³, Boris Hejblum¹²

¹University of Bordeaux

²Vaccine Research Institute, France

³CHU de Bordeaux


⁴Harvard Medical School

⁵RAND Corporation

24th July 2024


Vaccination

- Most **effective** measure in public health
 - **154 million** deaths prevented in 50 years
- Historically developed empirically




Transcriptomics

- **Gene expression:** Genes → Product



Transcriptomics in vaccinology


Experimental Design




Transcriptomics in vaccinology



Transcriptomics in vaccinology



Transcriptomics in vaccinology



Why study gene expression?

Huge potential :

Why study gene expression?

Huge potential :

- ✓ Holistic view of system
- ✓ Reveal vaccine mechanisms
- ✓ Observed early

Why study gene expression?

Huge potential :

- ✓ Holistic view of system
- ✓ Reveal vaccine mechanisms
- ✓ Observed early

But challenges with high-dimensionality...

Why study gene expression?


Huge potential :

- ✓ Holistic view of system
- ✓ Reveal vaccine mechanisms
- ✓ Observed early


But challenges with high-dimensionality...

- ⚠ Interpretability
- ⚠ Sensitivity to investigator choices
- ⚠ Low signal-noise ratio

Gene Set Approaches



Gene Set Approaches



- ✓ Reduced dimensionality
- ✓ Biological interpretability
- ✓ Boost signal

Comparing vaccine signatures reveals insight

nature immunology

Resource

<https://doi.org/10.1038/s41590-022-01329-6>

Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses

Received: 19 April 2022

Thomas Hagan^{1,2}, Bram Gerritsen^{1,3}, Lewis E. Tomalin^{1,4}, Slim Fourati^{1,5},

Accepted: 12 September 2022

Matthew P. Mullikin^{1,6}, Daniel G. Chauva^{1,7}, Dmitri Rychnov⁸, Evan Henrich⁹,

Published online: 31 October 2022

Helen E. R. Miller¹⁰, Joann Diray-Arce^{10,11}, Patrick Dunn¹², Audrey Lee¹³,

Check for updates

The Human Immunology Project Consortium (HIPC)¹¹, Ofer Levy^{14,15,16},Raphael Gottardo^{1,17,18}, Minne M. Sarawat¹, John S. Tsang¹,Mayte Suárez-Fariñas¹, Rafick-Pierre Sékaly¹, Steven H. Kleinstein^{1,2,19} andBali Pulendran^{1,20,21}nature
immunology

Systems biology of vaccination for seasonal influenza in humans

Helder I Nakaya^{1,2}, Jens Wrammer^{1,3}, Eva K Lee⁴, Luigi Racopoli^{5,6}, Stephanie Marie-Kamze^{1,2}, W Nicholas Haining⁷, Anthony R Means⁸, Sudhir P Kasturi^{1,2}, Nooruddin Khan^{1,2}, Gui-Mei Li^{1,2}, Megan McCausland^{1,2}, Vibhu Kanchan^{1,2}, Kenneth E Kokkola⁹, Shuzhao Li^{1,2}, Rivka Elbein⁹, Anesh K Mehta⁹, Alan Aderem¹⁰, Kanta Subbarao¹¹, Rafi Ahmed^{1,2} & Bali Pulendran^{1,2,12}

nature
immunology

Molecular signatures of antibody responses derived from a systems biology study of five human vaccines

Shuzhao Li^{1,2,10}, Nadine Rouphael^{1,3,10}, Sai Duraisingham^{1,2,10}, Sandra Romero-Steiner⁴, Scott Presnell^{5,6}, Carl Davis^{5,7}, Daniel S Schmidt⁴, Scott E Johnson⁴, Andrea Milton⁴, Govirsankar Rajani⁴, Sudhir Kasturi^{1,2}, George M Carlson⁴, Charlie Quinn^{5,6}, Damien Chaussabel^{3,4}, A Karolina Palucka⁶, Mark J Meiligan^{1,2,9}, Rafi Ahmed^{1,2}, David S Stephens^{1,2}, Helder I Nakaya^{1,2,9} & Bali Pulendran^{1,2,9}

Immunity
ResourceCell
PRESSnature
COMMUNICATIONS

Systems Scale Interactive Exploration Reveals Quantitative and Qualitative Differences in Response to Influenza and Pneumococcal Vaccines

Gerlinde Obermoser,¹ Scott Presnell,² Kelly Domico,² Hui Xu,³ Yuanyuan Wang,¹ Esperanza Anguiano,¹ LuAnn Thompson-Snipes,⁴ Rajaram Ranganathan,¹ Brad Zeitner,² Anna Bjork,² David Anderson,² Cate Speake,² Emily Ruchaud,¹ Jason Skinner,¹ Lala Alsina,¹ Manita Sharma,¹ Helene Dutarte,¹ Alma Cepika,¹ Elisabeth Israelsson,¹ Phuong Nguyen,¹ Quynh-Anh Nguyen,¹ A. Carson Harrod,¹ Sandra M. Zurawski,¹ Virginia Pascual,¹ Hideki Ueno,¹ Gerald T. Nepom,² Charles Quinn,^{1,2} Derek Blankenship,³ Karolina Palucka,^{1,7} Jacques Banchereau,¹ and Damien Chaussabel^{1,2,4}

ARTICLE

Received 2 Jun 2014 | Accepted 16 Sep 2014 | Published 22 Oct 2014


DOI: 10.1038/ncomms5283 OPEN

Transcriptional specialization of human dendritic cell subsets in response to microbial vaccines

Romain Banchereau,¹ Nicole Baldwin¹, Alma-Martina Cepika,¹ Shruti Athale¹, Yaming Xue¹, Chun I. Yu¹, Patrick Metang¹, Abhilasha Cherukuri¹, Isabelle Berthier¹, Ingrid Gayet¹, Yuanyuan Wang¹, Marina Ohouo,¹ LuAnn Snipes¹, Hui Xu¹, Gerlinde Obermoser¹, Derek Blankenship¹, Sangkon Oh¹, Octavio Ramilo², Damien Chaussabel^{1,2,4}, Jacques Banchereau^{1,5,*}, Karolina Palucka^{1,5,*} & Virginia Pascual^{1,4}


A statistical test for comparing signatures of vaccines

1. Gene-level Expression Profiles




A statistical test for comparing signatures of vaccines

1. Gene-level Expression Profiles




2. Gene Set Database




A statistical test for comparing signatures of vaccines


1. Gene-level Expression Profiles



2. Gene Set Database



3. Gene-set Comparative test



Working linear mixed effects model

Derive test statistic from

$$\mathbf{y}_i^G = \boldsymbol{\alpha}_0 + \mathbf{X}_i \boldsymbol{\alpha} + \Phi_i \boldsymbol{\beta} + \Phi_i \boldsymbol{\xi}_i + \epsilon_i$$

- $\mathbf{y}_i^G = ((\mathbf{y}_i^1)^T, \dots, (\mathbf{y}_i^p)^T)^T$ - expression of p genes in set G
- \mathbf{X}_i - covariates to control for
- Φ_i - K test variables

Working linear mixed effects model

Derive test statistic from

$$\mathbf{y}_i^G = \boldsymbol{\alpha}_0 + \mathbf{X}_i \boldsymbol{\alpha} + \Phi_i \boldsymbol{\beta} + \Phi_i \boldsymbol{\xi}_i + \epsilon_i$$

- $\mathbf{y}_i^G = ((\mathbf{y}_i^1)^T, \dots, (\mathbf{y}_i^p)^T)^T$ - expression of p genes in set G
- \mathbf{X}_i - covariates to control for
- Φ_i - K test variables

⇒ $\boldsymbol{\beta}$ - fixed effects of test variables

⇒ $\boldsymbol{\xi}_i \sim \mathcal{N}(\mathbf{0}, \Sigma_{\xi})$ - random effects of test variables

⇒ $\epsilon_i \sim \mathcal{N}(\mathbf{0}, \Sigma_i)$ - residual error

Working linear mixed effects model

Derive test statistic from

$$\mathbf{y}_i^G = \boldsymbol{\alpha}_0 + \mathbf{X}_i \boldsymbol{\alpha} + \Phi_i \boldsymbol{\beta} + \Phi_i \boldsymbol{\xi}_i + \epsilon_i$$

- $\mathbf{y}_i^G = ((\mathbf{y}_i^1)^T, \dots, (\mathbf{y}_i^p)^T)^T$ - expression of p genes in set G
- \mathbf{X}_i - covariates to control for
- Φ_i - K test variables

⇒ $\boldsymbol{\beta}$ - fixed effects of test variables

⇒ $\boldsymbol{\xi}_i \sim \mathcal{N}(\mathbf{0}, \Sigma_{\xi})$ - random effects of test variables

⇒ $\epsilon_i \sim \mathcal{N}(\mathbf{0}, \Sigma_i)$ - residual error

Null Hypothesis

$$H_0 : \boldsymbol{\beta} = \mathbf{0}, \Sigma_{\xi} = \mathbf{0}$$

Test statistic

The derived **variance-component score test statistic** is $Q = \mathbf{q}^T \mathbf{q}$ with

$$\mathbf{q}^T = n^{-1/2} \sum_{i=1}^n \underbrace{(\mathbf{y}_i^G - (\boldsymbol{\alpha}_0 + \mathbf{X}_i \boldsymbol{\alpha}))^T}_{\text{Gene-set expression}} \quad \begin{array}{c} \text{Gene-set Covariance} \\ \widehat{\Sigma_i^{-1}} \\ \underbrace{\Phi_i}_{\text{Vaccine indicator}} \end{array}$$

$$\implies Q \underset{+\infty}{\sim} \sum_{k=1}^{pK} a_k \chi_1^2 \quad \text{where } a_k \text{ is } k\text{th eigenvalue of } \text{cov}(\mathbf{q}).$$

Application : vaccine comparison

Yellow Fever 17D
(live attenuated)




Pneumococcus
(polysaccharide)




VS

⇒ **What differs between how these vaccines provoke immunity?**

Strong antiviral signal after Yellow Fever



Distinct dynamics of B-cell response



Lessons learnt : Yellow Fever vs Pneumococcus

- Characterised by **different immune responses**
- Early antiviral response may characterise yellow fever
- Yellow fever induces an early B-cell response

Take-home message

- The **potential and challenges** of gene expression for vaccine development
- A **statistical test for comparing pathways** activated through vaccination
- Illustrated **interpretable differences** between two vaccines

Take-home message

- The **potential and challenges** of gene expression for vaccine development
- A **statistical test for comparing pathways** activated through vaccination
- Illustrated **interpretable differences** between two vaccines


Thank you for listening!

References

-  Diray-Arce, Joann et al. (Oct. 2022). "The Immune Signatures data resource, a compendium of systems vaccinology datasets". In: *Scientific Data* 9.1. ISSN: 2052-4463.
-  Law, Charity W et al. (2014). "voom: precision weights unlock linear model analysis tools for RNA-seq read counts". In: *Genome Biology* 15.2, R29. ISSN: 1465-6906.
-  Pollard, Andrew J. and Else M. Bijker (Dec. 2020). "A guide to vaccinology: from basic principles to new developments". In: *Nature Reviews Immunology* 21.2, pp. 83–100. ISSN: 1474-1741.


Estimating the mean-variance relationship

⚠ RNA-seq is heteroskedastic \implies **Mean-variance relationship non-linear**




Estimating the mean-variance relationship

⚠ RNA-seq is heteroskedastic \implies **Mean-variance relationship non-linear**




Estimating the mean-variance relationship

⚠ RNA-seq is heteroskedastic \implies **Mean-variance relationship non-linear**



Estimating the mean-variance relationship

⚠ RNA-seq is heteroskedastic \implies **Mean-variance relationship non-linear**



Visualisation score

Define gene-level scores $q_i^g = (\mathbf{y}_i^g - (\boldsymbol{\alpha}_0 + \mathbf{x}_i \boldsymbol{\alpha}))\sigma_i^{-1}\phi_i$
where σ_i is the std. deviation of g

$i \in T$ if treated

$i \in C$ if control

$g = 1, \dots, p$ genes in a set G

Define the *visualisation score* :

$$d = \frac{1}{p} \sum_{g=1}^p \left\{ \frac{1}{|T|} \sum_{i \in T} q_i^g - \frac{1}{|C|} \sum_{i \in C} q_i^g \right\}$$

i.e. the **average difference in scores** between the two groups.

Human Immune Project Consortium

- **Public resources** to characterise human immune system
- 30 studies comprising 24 vaccines developed against 11 pathogens
 - **13 distinct vaccine types** (pathogen + vaccine platform)
- **4975 transcriptomic samples from 1405 individuals**
 - 10086 common genes across all studies



Limitations

- Typically choose Σ_i diagonal i.e. do not model within-gene set correlations
- Visualisation shows mean differences but there may be multiple trends within a gene set
- Test underpowered when model grossly misspecified